Fundies.
English

Segment disclosures

Company overview

PAR PHARMACEUTICAL COMPANIES, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

131 dimension combinations 768 retained observations 22 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Amlodipine Valsartan Exforge · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:AmlodipineValsartanExforgeMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20150313Open filing evidence

Operating Segments · Amlodipine Valsartan Exforge · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:AmlodipineValsartanExforgeMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3160784000 USD20150313Open filing evidence
2013-01-01 – 2013-12-310 USD20150313Open filing evidence
2012-09-29 – 2012-12-310 USD20150313Open filing evidence

Operating Segments · Aplisol · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:AplisolMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20150313Open filing evidence

Operating Segments · Aplisol · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:AplisolMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3135228000 USD20150313Open filing evidence
2013-01-01 – 2013-12-310 USD20150313Open filing evidence
2012-09-29 – 2012-12-310 USD20150313Open filing evidence

Operating Segments · Budesonide Entocort Ec · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:BudesonideEntocortEcMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-28103762000 USD20150313Open filing evidence
2011-01-01 – 2011-12-3170016000 USD20140318Open filing evidence

Operating Segments · Budesonide Entocort Ec · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:BudesonideEntocortEcMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-31142853000 USD20150313Open filing evidence
2013-01-01 – 2013-12-31198834000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3136710000 USD20150313Open filing evidence

Operating Segments · Bupropion Er Wellbutrin · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:BupropionErWellbutrinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2834952000 USD20150313Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Bupropion Er Wellbutrin · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:BupropionErWellbutrinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3184467000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3145403000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3111255000 USD20150313Open filing evidence

Operating Segments · Chlorpheniramine Hydrocodone Tussionex · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ChlorpheniramineHydrocodoneTussionexMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2830706000 USD20150313Open filing evidence
2011-01-01 – 2011-12-3139481000 USD20140318Open filing evidence

Operating Segments · Chlorpheniramine Hydrocodone Tussionex · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ChlorpheniramineHydrocodoneTussionexMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3126899000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3133518000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3117403000 USD20150313Open filing evidence

Operating Segments · Clonidine ER Kapvay · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ClonidineERKapvayMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20150313Open filing evidence

Operating Segments · Clonidine ER Kapvay · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ClonidineERKapvayMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3145134000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3113008000 USD20150313Open filing evidence
2012-09-29 – 2012-12-310 USD20150313Open filing evidence

Operating Segments · Diltiazem Cardizem CD · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:DiltiazemCardizemCDMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20140318Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Diltiazem Cardizem CD · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:DiltiazemCardizemCDMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-3127212000 USD20140318Open filing evidence
2012-09-29 – 2012-12-313702000 USD20140318Open filing evidence

Operating Segments · Divalproex Depakote · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:DivalproexDepakoteMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-289099000 USD20150313Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Divalproex Depakote · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:DivalproexDepakoteMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3159052000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3146635000 USD20150313Open filing evidence
2012-09-29 – 2012-12-312436000 USD20150313Open filing evidence

Operating Segments · Lamotrigine Lamictal Xr · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:LamotrigineLamictalXrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20150313Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Lamotrigine Lamictal Xr · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:LamotrigineLamictalXrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3140673000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3154577000 USD20150313Open filing evidence
2012-09-29 – 2012-12-310 USD20150313Open filing evidence

Operating Segments · Megace Es · Par Specialty · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2838322000 USD20150313Open filing evidence

Operating Segments · Megace Es · Par Specialty · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3131653000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3139510000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3110910000 USD20150313Open filing evidence

Operating Segments · Megace Es · Strativa · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2838322000 USD20140318Open filing evidence
2011-01-01 – 2011-12-3158172000 USD20140318Open filing evidence

Operating Segments · Megace Es · Strativa · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-3139510000 USD20140318Open filing evidence
2012-09-29 – 2012-12-3110910000 USD20140318Open filing evidence

Operating Segments · Metoprolol Succinate Er Toprol Xl · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MetoprololSuccinateErToprolXlMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-28154216000 USD20150313Open filing evidence
2011-01-01 – 2011-12-31250995000 USD20140318Open filing evidence

Operating Segments · Metoprolol Succinate Er Toprol Xl · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:MetoprololSuccinateErToprolXlMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3146251000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3156670000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3131287000 USD20150313Open filing evidence

Operating Segments · Modafinil Provigil · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ModafinilProvigilMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2888831000 USD20150313Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Modafinil Provigil · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:ModafinilProvigilMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-312123000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3127688000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3116956000 USD20150313Open filing evidence

Operating Segments · Nascobal Nasal Spray · Par Specialty · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2817571000 USD20150313Open filing evidence

Operating Segments · Nascobal Nasal Spray · Par Specialty · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3132332000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3126864000 USD20150313Open filing evidence
2012-09-29 – 2012-12-317138000 USD20150313Open filing evidence

Operating Segments · Nascobal Nasal Spray · Strativa · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2817571000 USD20140318Open filing evidence
2011-01-01 – 2011-12-3121399000 USD20140318Open filing evidence

Operating Segments · Nascobal Nasal Spray · Strativa · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-3126864000 USD20140318Open filing evidence
2012-09-29 – 2012-12-317138000 USD20140318Open filing evidence

Operating Segments · Other Generic Drugs · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-28249383000 USD20150313Open filing evidence
2011-01-01 – 2011-12-31374288000 USD20140318Open filing evidence

Operating Segments · Other Generic Drugs · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-31594751000 USD20150313Open filing evidence
2013-01-01 – 2013-12-31450148000 RestatedUSD20150313Open filing evidence
2012-09-29 – 2012-12-3183491000 RestatedUSD20150313Open filing evidence

Operating Segments · Other Generic Drugs · Strativa · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-28130000 USD20140318Open filing evidence
2011-01-01 – 2011-12-313309000 USD20140318Open filing evidence

Operating Segments · Other Generic Drugs · Strativa · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-31-910000 USD20140318Open filing evidence
2012-09-29 – 2012-12-31130000 USD20140318Open filing evidence

Operating Segments · Other Product Related Revenues · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2818586000 USD20150313Open filing evidence
2011-01-01 – 2011-12-3129977000 USD20140318Open filing evidence

Operating Segments · Other Product Related Revenues · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3126950000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3131429000 USD20150313Open filing evidence
2012-09-29 – 2012-12-318151000 USD20150313Open filing evidence

Operating Segments · Other Product Related Revenues · Par Specialty · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-284615000 USD20150313Open filing evidence

Operating Segments · Other Product Related Revenues · Par Specialty · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-313505000 USD20150313Open filing evidence
2013-01-01 – 2013-12-312675000 USD20150313Open filing evidence
2012-09-29 – 2012-12-31779000 USD20150313Open filing evidence

Operating Segments · Other Product Related Revenues · Strativa · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-284485000 USD20140318Open filing evidence
2011-01-01 – 2011-12-318666000 USD20140318Open filing evidence

Operating Segments · Other Product Related Revenues · Strativa · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-313585000 USD20140318Open filing evidence
2012-09-29 – 2012-12-31649000 USD20140318Open filing evidence

Operating Segments · Propafenone Rythmol Sr · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:PropafenoneRythmolSrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2853825000 USD20150313Open filing evidence
2011-01-01 – 2011-12-3169835000 USD20140318Open filing evidence

Operating Segments · Propafenone Rythmol Sr · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:PropafenoneRythmolSrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3175966000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3170508000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3119623000 USD20150313Open filing evidence

Operating Segments · Rizatriptan Maxalt · Par Pharmaceutical · Predecessor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:RizatriptanMaxaltMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-280 USD20140318Open filing evidence
2011-01-01 – 2011-12-310 USD20140318Open filing evidence

Operating Segments · Rizatriptan Maxalt · Par Pharmaceutical · Successor

Consolidation Items · Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ProductOrServiceAxis=prx:RizatriptanMaxaltMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-3145598000 USD20140318Open filing evidence
2012-09-29 – 2012-12-310 USD20140318Open filing evidence

Operating Segments · Par Pharmaceutical · Predecessor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-28743360000 USD20150313Open filing evidence
2011-01-01 – 2011-12-31834592000 USD20140318Open filing evidence

Operating Segments · Par Pharmaceutical · Successor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-311241131000 USD20150313Open filing evidence
2013-01-01 – 2013-12-311028418000 USD20150313Open filing evidence
2012-09-29 – 2012-12-31227312000 USD20150313Open filing evidence

Operating Segments · Par Specialty · Predecessor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2860508000 USD20150313Open filing evidence

Operating Segments · Par Specialty · Successor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-12-3167490000 USD20150313Open filing evidence
2013-01-01 – 2013-12-3169049000 USD20150313Open filing evidence
2012-09-29 – 2012-12-3118827000 USD20150313Open filing evidence

Operating Segments · Strativa · Predecessor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-09-2860508000 USD20140318Open filing evidence
2011-01-01 – 2011-12-3191546000 USD20140318Open filing evidence

Operating Segments · Strativa · Successor

Consolidation Items · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-01-01 – 2013-12-3169049000 USD20140318Open filing evidence
2012-09-29 – 2012-12-3118827000 USD20140318Open filing evidence

Amlodipine And Benazepril Hci Lotrel · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:AmlodipineAndBenazeprilHciLotrelMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-301729000 USD20120802Open filing evidence
2012-01-01 – 2012-06-304177000 USD20120802Open filing evidence
2012-01-01 – 2012-03-312448000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3137310000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-304467000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3035143000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3012505000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3012505000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3030675000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3030675000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3118171000 Unit1220120508Open filing evidence

Amlodipine Valsartan Exforge · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:AmlodipineValsartanExforgeMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-01-01 – 2015-03-3118762000 USD20150511Open filing evidence
2014-01-01 – 2014-03-310 USD20150511Open filing evidence

Aplisol · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:AplisolMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-01-01 – 2015-03-3111500000 USD20150511Open filing evidence
2014-01-01 – 2014-03-314070000 USD20150511Open filing evidence

Budesonide Entocort Ec · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:BudesonideEntocortEcMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3028042000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3056919000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3128878000 USD20150511Open filing evidence
2014-07-01 – 2014-09-3032065000 USD20141112Open filing evidence
2014-01-01 – 2014-09-30107680000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3038266000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3075615000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3137349000 USD20150511Open filing evidence
2013-07-01 – 2013-09-3054952000 USD20141112Open filing evidence
2013-01-01 – 2013-09-30150382000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3045027000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3095430000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3150403000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3033513000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3071497000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3137984000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3170016000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3020551000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3036908000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3016357000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3016357000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3016357000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3016357000 USD20120802Open filing evidence

Budesonide Entocort Ec · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:BudesonideEntocortEcMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2833046000 USD20131112Open filing evidence
2012-01-01 – 2012-09-28104543000 USD20131112Open filing evidence

Budesonide Entocort Ec · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:BudesonideEntocortEcMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3054952000 USD20131112Open filing evidence
2013-01-01 – 2013-09-30150382000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Bupropion Er Wellbutrin · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:BupropionErWellbutrinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3020524000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3042086000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3121562000 USD20150511Open filing evidence
2014-07-01 – 2014-09-3016581000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3051346000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3018423000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3034765000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3116342000 USD20150511Open filing evidence
2013-07-01 – 2013-09-3011450000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3031268000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3011565000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3019817000 USD20140811Open filing evidence
2013-01-01 – 2013-03-318253000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3012010000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3023364000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3111354000 Unit1220120508Open filing evidence
2011-04-01 – 2011-06-300 USD20120802Open filing evidence
2011-01-01 – 2011-06-300 USD20120802Open filing evidence

Bupropion Er Wellbutrin · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:BupropionErWellbutrinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2812695000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2836059000 USD20131112Open filing evidence

Bupropion Er Wellbutrin · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:BupropionErWellbutrinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3011450000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3031268000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Cabergoline Dostinex · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:CabergolineDostinexMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-3112186000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-302998000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-308871000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-302920000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-305873000 Unit1220110803Open filing evidence
2010-01-01 – 2010-12-3112487000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-303221000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-309735000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-302520000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-306514000 Unit1220110803Open filing evidence

Chlorpheniramine Hydrocodone Tussionex · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:ChlorpheniramineHydrocodoneTussionexMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-307984000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3021941000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3113957000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3139481000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-304854000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3024555000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-307022000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-307022000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3019701000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3019701000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3112679000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3117479000 Unit1220120228Open filing evidence

Cholestyramine Powder Questran · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:CholestyraminePowderQuestranMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-304958000 USD20120802Open filing evidence
2012-01-01 – 2012-06-309878000 USD20120802Open filing evidence
2012-01-01 – 2012-03-314652000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3116144000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-303789000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3011549000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-304077000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-304077000 USD20120802Open filing evidence
2011-01-01 – 2011-06-307760000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-307760000 USD20120802Open filing evidence
2011-01-01 – 2011-03-313683000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3116007000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-304850000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3011761000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-302974000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-306910000 Unit1220110803Open filing evidence

Clonidine Tds Catapres Tts · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:ClonidineTdsCatapresTtsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-01-01 – 2012-03-31-991000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-314094000 Unit1220120228Open filing evidence
2011-01-01 – 2011-09-305225000 Unit1220111102Open filing evidence
2011-01-01 – 2011-06-304793000 Unit1220110803Open filing evidence
2011-01-01 – 2011-03-315806000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3161272000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-307848000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3052599000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-3026290000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-3044751000 Unit1220110803Open filing evidence

Cortisporin TC · Par Specialty

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:CortisporinTCMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-302010000 USD20150806Open filing evidence
2015-01-01 – 2015-06-302010000 USD20150806Open filing evidence
2014-04-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-06-300 USD20150806Open filing evidence

Divalproex Depakote · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:DivalproexDepakoteMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-308522000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3016984000 USD20150806Open filing evidence
2015-01-01 – 2015-03-318462000 USD20150511Open filing evidence
2014-07-01 – 2014-09-3010849000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3046765000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3015511000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3035917000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3120405000 USD20150511Open filing evidence
2013-07-01 – 2013-09-3026343000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3020116000 USD20141112Open filing evidence
2013-04-01 – 2013-06-30-7653000 USD20140811Open filing evidence
2013-01-01 – 2013-06-30-6227000 USD20140811Open filing evidence
2013-01-01 – 2013-03-311426000 USD20140515Open filing evidence

Divalproex Depakote · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:DivalproexDepakoteMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-282772000 USD20131112Open filing evidence
2012-01-01 – 2012-09-289353000 USD20131112Open filing evidence

Divalproex Depakote · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:DivalproexDepakoteMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3026343000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3020116000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Dronabinol Marinol · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:DronabinolMarinolMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-304444000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3012047000 USD20120802Open filing evidence
2012-01-01 – 2012-03-317603000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3129880000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-307208000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3022197000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-308118000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-308118000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3014989000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3014989000 USD20120802Open filing evidence
2011-01-01 – 2011-03-316871000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3127232000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-309073000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3020347000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-307183000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-3011274000 Unit1220110803Open filing evidence

Lamotrigine Lamictal Xr · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:LamotrigineLamictalXrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-308789000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3029185000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3010262000 USD20140811Open filing evidence
2014-01-01 – 2014-06-3020396000 USD20140811Open filing evidence
2013-07-01 – 2013-09-3011079000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3041725000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3010535000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3030646000 USD20140811Open filing evidence

Lamotrigine Lamictal Xr · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:LamotrigineLamictalXrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-280 USD20131112Open filing evidence
2012-01-01 – 2012-09-280 USD20131112Open filing evidence

Lamotrigine Lamictal Xr · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:LamotrigineLamictalXrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3011079000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3041725000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Meclizine Hydrochloride Antivert · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:MeclizineHydrochlorideAntivertMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-303783000 USD20120802Open filing evidence
2012-01-01 – 2012-06-307969000 USD20120802Open filing evidence
2012-01-01 – 2012-03-314186000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3117184000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-303859000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3013295000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-304562000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-304562000 USD20120802Open filing evidence
2011-01-01 – 2011-06-309437000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-309437000 USD20120802Open filing evidence
2011-01-01 – 2011-03-314875000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3131216000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-306219000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3025771000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-309398000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-3019552000 Unit1220110803Open filing evidence

Megace Es · Par Specialty

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-305338000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3010324000 USD20150806Open filing evidence
2015-01-01 – 2015-03-314986000 USD20150511Open filing evidence
2014-04-01 – 2014-06-307779000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3015932000 USD20150806Open filing evidence
2014-01-01 – 2014-03-318153000 USD20150511Open filing evidence

Megace Es · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-307712000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3023644000 USD20141112Open filing evidence
2014-04-01 – 2014-06-307779000 USD20140811Open filing evidence
2014-01-01 – 2014-06-3015932000 USD20140811Open filing evidence
2014-01-01 – 2014-03-318154000 USD20140515Open filing evidence
2013-07-01 – 2013-09-309455000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3031009000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3011018000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3021553000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3110536000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3014212000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3026390000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3112178000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3158172000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3014228000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3042362000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3014050000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3014050000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3028135000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3028135000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3114085000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3160879000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3016806000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3046097000 Unit1220111102Open filing evidence
2010-04-01 – 2010-06-3015493000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-3029291000 Unit1220110803Open filing evidence

Megace Es · Strativa · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2812279000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2838670000 USD20131112Open filing evidence

Megace Es · Strativa · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:MegaceEsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-309455000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3031009000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Megestrol Oral Suspension Megace · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:MegestrolOralSuspensionMegaceMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-3111959000 Unit1220120228Open filing evidence
2010-01-01 – 2010-12-3112556000 Unit1220120228Open filing evidence

Methimazole Tapazole · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:MethimazoleTapazoleMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-318756000 Unit1220120228Open filing evidence
2011-04-01 – 2011-06-302456000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-304560000 Unit1220110803Open filing evidence
2010-01-01 – 2010-12-3110649000 Unit1220120228Open filing evidence
2010-04-01 – 2010-06-302590000 Unit1220110803Open filing evidence
2010-01-01 – 2010-06-305430000 Unit1220110803Open filing evidence

Metoprolol Succinate Er Toprol Xl · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:MetoprololSuccinateErToprolXlMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3012055000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3023077000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3111022000 USD20150511Open filing evidence
2014-07-01 – 2014-09-309312000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3035525000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3012096000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3026213000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3114117000 USD20150511Open filing evidence
2013-07-01 – 2013-09-3012277000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3045206000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3013527000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3032929000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3119401000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3048953000 USD20120802Open filing evidence
2012-01-01 – 2012-06-30110718000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3161765000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-31250995000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3067509000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-30194634000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3063706000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3063706000 USD20120802Open filing evidence
2011-01-01 – 2011-06-30127124000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-30127124000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3163418000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-31473206000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3097360000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-30400247000 Unit1220111102Open filing evidence
2010-01-01 – 2010-06-30302887000 Unit1220110803Open filing evidence

Metoprolol Succinate Er Toprol Xl · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:MetoprololSuccinateErToprolXlMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2845875000 USD20131112Open filing evidence
2012-01-01 – 2012-09-28156593000 USD20131112Open filing evidence

Metoprolol Succinate Er Toprol Xl · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:MetoprololSuccinateErToprolXlMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3012277000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3045206000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Modafinil Provigil · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:ModafinilProvigilMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-3057484000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3057484000 USD20120802Open filing evidence
2011-04-01 – 2011-06-300 USD20120802Open filing evidence
2011-01-01 – 2011-06-300 USD20120802Open filing evidence

Modafinil Provigil · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:ModafinilProvigilMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2832683000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2890166000 USD20131112Open filing evidence

Modafinil Provigil · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:ModafinilProvigilMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-30-225000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3022530000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Nascobal Nasal Spray · Par Specialty

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-309339000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3015842000 USD20150806Open filing evidence
2015-01-01 – 2015-03-316504000 USD20150511Open filing evidence
2014-04-01 – 2014-06-308172000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3014496000 USD20150806Open filing evidence
2014-01-01 – 2014-03-316325000 USD20150511Open filing evidence

Nascobal Nasal Spray · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-308457000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3022953000 USD20141112Open filing evidence
2014-04-01 – 2014-06-308172000 USD20140811Open filing evidence
2014-01-01 – 2014-06-3014496000 USD20140811Open filing evidence
2014-01-01 – 2014-03-316324000 USD20140515Open filing evidence
2013-07-01 – 2013-09-307592000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3020596000 USD20141112Open filing evidence
2013-04-01 – 2013-06-306801000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3013003000 USD20140811Open filing evidence
2013-01-01 – 2013-03-316202000 USD20140515Open filing evidence
2012-04-01 – 2012-06-305380000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3011312000 USD20120802Open filing evidence
2012-01-01 – 2012-03-315931000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3121399000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-304665000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3014816000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-306274000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-306274000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3010152000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3010152000 USD20120802Open filing evidence
2011-01-01 – 2011-03-313878000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3117715000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-304922000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3012924000 Unit1220111102Open filing evidence

Nascobal Nasal Spray · Strativa · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-286382000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2817693000 USD20131112Open filing evidence

Nascobal Nasal Spray · Strativa · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:NascobalNasalSprayMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-307592000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3020596000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Nateglinide · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:NateglinideMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-3115157000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-303213000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3011333000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-303815000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-308120000 Unit1220110803Open filing evidence
2010-01-01 – 2010-12-3115287000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-305960000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3010948000 Unit1220111102Open filing evidence

Nateglinide Starlix · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:NateglinideStarlixMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-303518000 USD20120802Open filing evidence
2012-01-01 – 2012-06-307542000 USD20120802Open filing evidence
2012-01-01 – 2012-03-314024000 Unit1220120508Open filing evidence
2011-04-01 – 2011-06-303815000 USD20120802Open filing evidence
2011-01-01 – 2011-06-308120000 USD20120802Open filing evidence
2011-01-01 – 2011-03-314306000 Unit1220120508Open filing evidence

Omega3acidethylesters Lovaza · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:Omega3acidethylestersLovazaMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3017207000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3040641000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3123434000 USD20150511Open filing evidence
2014-04-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-03-310 USD20150511Open filing evidence

Omega3 Lovaza · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:Omega3LovazaMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-3017716000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3017716000 USD20141112Open filing evidence
2013-07-01 – 2013-09-300 USD20141112Open filing evidence
2013-01-01 – 2013-09-300 USD20141112Open filing evidence

Omeprazole Zegerid · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:OmeprazoleZegeridMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-3114926000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-303853000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3011037000 Unit1220111102Open filing evidence
2010-01-01 – 2010-12-3118476000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3013508000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3014085000 Unit1220111102Open filing evidence

Oravigtm · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:OravigtmMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-30-3000 USD20120802Open filing evidence
2012-01-01 – 2012-06-30152000 USD20120802Open filing evidence
2012-01-01 – 2012-03-31155000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-312434000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-30477000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-302253000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-301027000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-301027000 USD20120802Open filing evidence
2011-01-01 – 2011-06-301776000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-301776000 USD20120802Open filing evidence
2011-01-01 – 2011-03-31749000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-311137000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-30101000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-30101000 Unit1220111102Open filing evidence

Other Generic Drugs · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-30172169000 USD20150806Open filing evidence
2015-01-01 – 2015-06-30379083000 USD20150806Open filing evidence
2015-01-01 – 2015-03-31179038000 USD20150511Open filing evidence
2014-07-01 – 2014-09-30126959000 USD20141112Open filing evidence
2014-01-01 – 2014-09-30386369000 USD20141112Open filing evidence
2014-04-01 – 2014-06-30174286000 RestatedUSD20150806Open filing evidence
2014-01-01 – 2014-06-30333328000 RestatedUSD20150806Open filing evidence
2014-01-01 – 2014-03-31154972000 RestatedUSD20150511Open filing evidence
2013-07-01 – 2013-09-30101788000 USD20141112Open filing evidence
2013-01-01 – 2013-09-30330624000 USD20141112Open filing evidence
2013-04-01 – 2013-06-30113115000 USD20140811Open filing evidence
2013-01-01 – 2013-06-30228838000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3198402000 USD20140515Open filing evidence

Other Generic Drugs · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2867908000 USD20131112Open filing evidence
2012-01-01 – 2012-09-28273503000 USD20131112Open filing evidence

Other Generic Drugs · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-30102013000 USD20131112Open filing evidence
2013-01-01 – 2013-09-30308094000 USD20131112Open filing evidence
2012-09-29 – 2012-09-3010689000 USD20131112Open filing evidence

Other Generic Drugs · Strativa

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-30-1000 USD20141112Open filing evidence
2014-01-01 – 2014-09-30-47000 USD20141112Open filing evidence
2014-04-01 – 2014-06-30-35000 USD20140811Open filing evidence
2014-01-01 – 2014-06-30-46000 USD20140811Open filing evidence
2014-01-01 – 2014-03-31-12000 USD20140515Open filing evidence
2013-07-01 – 2013-09-30-398000 USD20141112Open filing evidence
2013-01-01 – 2013-09-30-877000 USD20141112Open filing evidence
2013-04-01 – 2013-06-30-236000 USD20140811Open filing evidence
2013-01-01 – 2013-06-30-479000 USD20140811Open filing evidence
2013-01-01 – 2013-03-31-241000 USD20140515Open filing evidence

Other Generic Drugs · Strativa · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-280 USD20131112Open filing evidence
2012-01-01 – 2012-09-280 USD20131112Open filing evidence

Other Generic Drugs · Strativa · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherGenericDrugsMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-30-398000 USD20131112Open filing evidence
2013-01-01 – 2013-09-30-877000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Other Product Related Revenues · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-305710000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3010687000 USD20150806Open filing evidence
2015-01-01 – 2015-03-314977000 USD20150511Open filing evidence
2014-07-01 – 2014-09-308810000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3019236000 USD20141112Open filing evidence
2014-04-01 – 2014-06-304986000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3010425000 USD20150806Open filing evidence
2014-01-01 – 2014-03-315439000 USD20150511Open filing evidence
2013-07-01 – 2013-09-307223000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3022197000 USD20141112Open filing evidence
2013-04-01 – 2013-06-308196000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3014974000 USD20140811Open filing evidence
2013-01-01 – 2013-03-316779000 USD20140515Open filing evidence
2012-04-01 – 2012-06-306795000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3012189000 USD20120802Open filing evidence
2012-01-01 – 2012-03-315393000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3129977000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-306192000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3023126000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-309045000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-309045000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3016934000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3016934000 USD20120802Open filing evidence
2011-01-01 – 2011-03-317889000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3116243000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-305445000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-309698000 Unit1220111102Open filing evidence

Other Product Related Revenues · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-286398000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2818456000 USD20131112Open filing evidence

Other Product Related Revenues · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-307223000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3022197000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Other Product Related Revenues · Par Specialty

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-30766000 USD20150806Open filing evidence
2015-01-01 – 2015-06-301892000 USD20150806Open filing evidence
2015-01-01 – 2015-03-311125000 USD20150511Open filing evidence
2014-04-01 – 2014-06-30620000 USD20150806Open filing evidence
2014-01-01 – 2014-06-301421000 USD20150806Open filing evidence
2014-01-01 – 2014-03-31800000 USD20150511Open filing evidence

Other Product Related Revenues · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-301165000 USD20141112Open filing evidence
2014-01-01 – 2014-09-302632000 USD20141112Open filing evidence
2014-04-01 – 2014-06-30655000 USD20140811Open filing evidence
2014-01-01 – 2014-06-301467000 USD20140811Open filing evidence
2014-01-01 – 2014-03-31812000 USD20140515Open filing evidence
2013-07-01 – 2013-09-30854000 USD20141112Open filing evidence
2013-01-01 – 2013-09-302725000 USD20141112Open filing evidence
2013-04-01 – 2013-06-30971000 USD20140811Open filing evidence
2013-01-01 – 2013-06-301871000 USD20140811Open filing evidence
2013-01-01 – 2013-03-31899000 USD20140515Open filing evidence
2012-04-01 – 2012-06-301741000 USD20120802Open filing evidence
2012-01-01 – 2012-06-303696000 USD20120802Open filing evidence
2012-01-01 – 2012-03-311956000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-318666000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-30300000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-304699000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-30125000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-30125000 USD20120802Open filing evidence
2011-01-01 – 2011-06-304399000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-304399000 USD20120802Open filing evidence
2011-01-01 – 2011-03-314274000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3112000000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-302864000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-309000000 Unit1220111102Open filing evidence

Other Product Related Revenues · Strativa · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-28788000 USD20131112Open filing evidence
2012-01-01 – 2012-09-284615000 USD20131112Open filing evidence

Other Product Related Revenues · Strativa · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:OtherProductRelatedRevenuesMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-30854000 USD20131112Open filing evidence
2013-01-01 – 2013-09-302725000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Oxycodone Oxycontin · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:OxycodoneOxycontinMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3013812000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3016197000 USD20150806Open filing evidence
2014-07-01 – 2014-09-3018334000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3018334000 USD20141112Open filing evidence
2014-04-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-06-300 USD20150806Open filing evidence
2013-07-01 – 2013-09-300 USD20141112Open filing evidence
2013-01-01 – 2013-09-300 USD20141112Open filing evidence

Par Sterile Products · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:ParSterileProductsMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-3046751000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3096479000 USD20141112Open filing evidence
2013-07-01 – 2013-09-300 USD20141112Open filing evidence
2013-01-01 – 2013-09-300 USD20141112Open filing evidence

Propafenone Rythmol Sr · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:PropafenoneRythmolSrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3011489000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3023660000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3112171000 USD20150511Open filing evidence
2014-07-01 – 2014-09-3018858000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3055235000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3015266000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3036377000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3121112000 USD20150511Open filing evidence
2013-07-01 – 2013-09-3019423000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3053919000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3017337000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3034496000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3117159000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3017888000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3036980000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3119092000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3169835000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3018083000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3053432000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3013311000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3013311000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3035350000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3035350000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3122039000 Unit1220120508Open filing evidence

Propafenone Rythmol Sr · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:PropafenoneRythmolSrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2817237000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2854217000 USD20131112Open filing evidence

Propafenone Rythmol Sr · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:PropafenoneRythmolSrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3019423000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3053919000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Propranolol Hcl Er Inderal La · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:PropranololHclErInderalLaMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2011-01-01 – 2011-12-31154000 Unit1220120228Open filing evidence
2010-01-01 – 2010-12-315870000 Unit1220120228Open filing evidence

Rizatriptan Maxalt · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:RizatriptanMaxaltMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-303760000 USD20141112Open filing evidence
2014-01-01 – 2014-09-307555000 USD20141112Open filing evidence
2014-04-01 – 2014-06-301597000 USD20140811Open filing evidence
2014-01-01 – 2014-06-303795000 USD20140811Open filing evidence
2013-07-01 – 2013-09-305283000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3042296000 USD20141112Open filing evidence
2013-04-01 – 2013-06-303466000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3037014000 USD20140811Open filing evidence

Rizatriptan Maxalt · Par Pharmaceutical · Predecessor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:RizatriptanMaxaltMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-280 USD20131112Open filing evidence
2012-01-01 – 2012-09-280 USD20131112Open filing evidence

Rizatriptan Maxalt · Par Pharmaceutical · Successor

Product Or Service · Statement Business Segments · Statement Scenario

Source dimensions us-gaap:ProductOrServiceAxis=prx:RizatriptanMaxaltMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-305283000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3042296000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence

Sumatriptan Succinate Injection Imitrex · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:SumatriptanSuccinateInjectionImitrexMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-3013945000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3030644000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3116700000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3164068000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3016795000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3048777000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3015284000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3015284000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3031983000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3031983000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3116699000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3172984000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3018315000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3053062000 Unit1220111102Open filing evidence

Total Par Pharmaceutical · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:TotalParPharmaceuticalMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-30273109000 USD20120802Open filing evidence
2012-01-01 – 2012-06-30524276000 USD20120802Open filing evidence
2012-01-01 – 2012-03-31251167000 Unit1220120508Open filing evidence
2011-04-01 – 2011-06-30202449000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-30202449000 USD20120802Open filing evidence
2011-01-01 – 2011-06-30412193000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-30412193000 USD20120802Open filing evidence
2011-01-01 – 2011-03-31209745000 Unit1220120508Open filing evidence

Total Strativa · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:TotalStrativaMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-3021224000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3041529000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3120305000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3191546000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3019905000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3064851000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3021739000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3021739000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3044947000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3044947000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3123207000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3191944000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3024693000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3068122000 Unit1220111102Open filing evidence

Tramadol Er Ultracet Er · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:TramadolErUltracetErMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-304593000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3010422000 USD20120802Open filing evidence
2012-01-01 – 2012-03-315829000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3124980000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-306280000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3018233000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-305873000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-305873000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3011954000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3011954000 USD20120802Open filing evidence
2011-01-01 – 2011-03-316081000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3122640000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-305546000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3016508000 Unit1220111102Open filing evidence

Vasostrict · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3025238000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3052062000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3126823000 USD20150511Open filing evidence
2014-04-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-06-300 USD20150806Open filing evidence
2014-01-01 – 2014-03-310 USD20150511Open filing evidence

Zolpidem Ambien Cr · Par Pharmaceutical

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=prx:ZolpidemAmbienCrMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-305342000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3012264000 USD20120802Open filing evidence
2012-01-01 – 2012-03-316921000 Unit1220120508Open filing evidence
2011-04-01 – 2011-06-300 USD20120802Open filing evidence
2011-01-01 – 2011-06-300 USD20120802Open filing evidence

Zuplenz · Strativa

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=prx:ZuplenzMember;us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-30-106000 USD20120802Open filing evidence
2012-01-01 – 2012-06-30-21000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3185000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-31875000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-30235000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-30721000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-30263000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-30263000 USD20120802Open filing evidence
2011-01-01 – 2011-06-30485000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-30485000 USD20120802Open filing evidence
2011-01-01 – 2011-03-31221000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-31213000 Unit1220120228Open filing evidence

Other · Par Pharmaceutical

Product Or Service · Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:ProductOrServiceAxis=us-gaap:OtherMember;us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2012-04-01 – 2012-06-3046170000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3095160000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3150250000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-31117490000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3025801000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3089331000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3033398000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3038774000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3066583000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3081809000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3137228000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-31103326000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3032402000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3088963000 Unit1220111102Open filing evidence

Par Pharmaceutical

Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-30314768000 USD20150806Open filing evidence
2015-01-01 – 2015-06-30661396000 USD20150806Open filing evidence
2015-01-01 – 2015-03-31346629000 USD20150511Open filing evidence
2014-07-01 – 2014-09-30318784000 USD20141112Open filing evidence
2014-01-01 – 2014-09-30871425000 USD20141112Open filing evidence
2014-04-01 – 2014-06-30278834000 USD20150806Open filing evidence
2014-01-01 – 2014-06-30552640000 USD20150806Open filing evidence
2014-01-01 – 2014-03-31273806000 USD20150511Open filing evidence
2013-07-01 – 2013-09-30249818000 USD20141112Open filing evidence
2013-01-01 – 2013-09-30737733000 USD20141112Open filing evidence
2013-04-01 – 2013-06-30215115000 USD20140811Open filing evidence
2013-01-01 – 2013-06-30487917000 USD20140811Open filing evidence
2013-01-01 – 2013-03-31272800000 USD20140515Open filing evidence
2012-04-01 – 2012-06-30273109000 USD20120802Open filing evidence
2012-01-01 – 2012-06-30524276000 USD20120802Open filing evidence
2012-01-01 – 2012-03-31251167000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-31834592000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-30195452000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-30607646000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-30202449000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-30202449000 USD20120802Open filing evidence
2011-01-01 – 2011-06-30412193000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-30412193000 USD20120802Open filing evidence
2011-01-01 – 2011-03-31209745000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-31916930000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-30209747000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-30713724000 Unit1220111102Open filing evidence

Par Pharmaceutical · Predecessor

Statement Business Segments · Statement Scenario

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-28218614000 USD20131112Open filing evidence
2012-01-01 – 2012-09-28742890000 USD20131112Open filing evidence

Par Pharmaceutical · Successor

Statement Business Segments · Statement Scenario

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:ParPharmaceuticalMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-30249818000 USD20131112Open filing evidence
2013-01-01 – 2013-09-30737733000 USD20131112Open filing evidence
2012-09-29 – 2012-09-3010689000 USD20131112Open filing evidence

Par Specialty

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:ParSpecialtyMember
PeriodValueUnitFiledEvidence
2015-04-01 – 2015-06-3017453000 USD20150806Open filing evidence
2015-01-01 – 2015-06-3030068000 USD20150806Open filing evidence
2015-01-01 – 2015-03-3112615000 USD20150511Open filing evidence
2014-04-01 – 2014-06-3016571000 USD20150806Open filing evidence
2014-01-01 – 2014-06-3031849000 USD20150806Open filing evidence
2014-01-01 – 2014-03-3115278000 USD20150511Open filing evidence

Strativa

Statement Business Segments

Multiple units reported for the same period; values are kept separate.

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-3017333000 USD20141112Open filing evidence
2014-01-01 – 2014-09-3049182000 USD20141112Open filing evidence
2014-04-01 – 2014-06-3016571000 USD20140811Open filing evidence
2014-01-01 – 2014-06-3031849000 USD20140811Open filing evidence
2014-01-01 – 2014-03-3115278000 USD20140515Open filing evidence
2013-07-01 – 2013-09-3017503000 USD20141112Open filing evidence
2013-01-01 – 2013-09-3053453000 USD20141112Open filing evidence
2013-04-01 – 2013-06-3018554000 USD20140811Open filing evidence
2013-01-01 – 2013-06-3035948000 USD20140811Open filing evidence
2013-01-01 – 2013-03-3117396000 USD20140515Open filing evidence
2012-04-01 – 2012-06-3021224000 USD20120802Open filing evidence
2012-01-01 – 2012-06-3041529000 USD20120802Open filing evidence
2012-01-01 – 2012-03-3120305000 Unit1220120508Open filing evidence
2011-01-01 – 2011-12-3191546000 Unit1220120228Open filing evidence
2011-07-01 – 2011-09-3019905000 Unit1220111102Open filing evidence
2011-01-01 – 2011-09-3064851000 Unit1220111102Open filing evidence
2011-04-01 – 2011-06-3021739000 Unit1220110803Open filing evidence
2011-04-01 – 2011-06-3021739000 USD20120802Open filing evidence
2011-01-01 – 2011-06-3044947000 Unit1220110803Open filing evidence
2011-01-01 – 2011-06-3044947000 USD20120802Open filing evidence
2011-01-01 – 2011-03-3123207000 Unit1220120508Open filing evidence
2010-01-01 – 2010-12-3191944000 Unit1220120228Open filing evidence
2010-07-01 – 2010-09-3024693000 Unit1220111102Open filing evidence
2010-01-01 – 2010-09-3068122000 Unit1220111102Open filing evidence

Strativa · Predecessor

Statement Business Segments · Statement Scenario

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:PredecessorMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-2819449000 USD20131112Open filing evidence
2012-01-01 – 2012-09-2860978000 USD20131112Open filing evidence

Strativa · Successor

Statement Business Segments · Statement Scenario

Source dimensions us-gaap:StatementBusinessSegmentsAxis=prx:StrativaMember;us-gaap:StatementScenarioAxis=us-gaap:SuccessorMember
PeriodValueUnitFiledEvidence
2013-07-01 – 2013-09-3017503000 USD20131112Open filing evidence
2013-01-01 – 2013-09-3053453000 USD20131112Open filing evidence
2012-09-29 – 2012-09-300 USD20131112Open filing evidence